Search

Displaying results 1511 - 1520 of 10000 in total
  1. Target

    Non-selective voltage-gated ion channel VDAC3

    go.drugbank.com/bio_entities/BE0002470
    TargetHumans

    Non-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:31935282).

    Polypeptides: Non-selective voltage-gated ion channel VDAC3
  2. Target

    Tyrosine-protein phosphatase non-receptor type 12

    go.drugbank.com/bio_entities/BE0009940
    TargetHumans

    Dephosphorylates a range of proteins, and thereby regulates cellular signaling cascades (PubMed:18559503). Dephosphorylates cellular tyrosine kinases, such as ERBB2 and PTK2B/PYK2, and thereby regulates signaling via ERBB2 and PTK2B/PYK2...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 12Function: non-membrane spanning protein tyrosine phosphatase activity
  3. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

    Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium
  4. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST

  5. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated … producers, and against non-enzymatic resistance mechanisms such as efflux and porin loss.

  6. Drug

    Mannitol

    go.drugbank.com/drugs/DB00742
    ApprovedInvestigational

    this indication under the name BRONCHITOL® by Chiesi USA Inc. … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for

  7. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    [L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

  8. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. … A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period

  9. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    In general, the drug was well tolerated by patients during cardiac examinations [A32091]. … Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.

    Categories: X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated
  10. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table.

    Mixtures: Co-HE-O2-N2 Mixture